

**RECEIVED
CENTRAL FAX CENTER**Intarcia Dkt No. ALE 058.11
USSN: 09/627,531
PATENT**MAR 13 2008**

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)	
I hereby certify that this correspondence is being facsimile transmitted to the Commissioner for Patents, United States Patent and Trademark Office, (Fax No. 571-273-8300) on the date indicated.	
Signature <i>Gary R. Fabara</i>	Date of Transmittal <i>13 March 2008</i>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE	
In Re Application of: BERRY, Stephen A., et al.	Confirmation No.: 3299
Serial No.: 09/627,531	Art Unit: 1618
Filing Date: 28 July 2000	Examiner: Fubara, B.M.
Title: Stable Non-Aqueous Single Phase Viscous Vehicles and Formulations Utilizing Such Vehicles	

**SECOND REQUEST
FOR USPTO TO ENTER NEW POWER OF ATTORNEY,
CHANGE OF BIBLIOGRAPHIC DATA AND
BLANKET PETITION**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

On 28 January 2008, applicants filed the following documents with the USPTO via facsimile:

1. Transmittal;
2. Revocation and Substitute Power of Attorney;
3. Change of Bibliographic Data: Attorney Docket Number and Correspondence Address; and
4. Authorization to Charge or Credit Deposit Account and Blanket Petition for Extension of Time.

Copies of the documents accompany this paper, including the USPTO Auto-Reply Facsimile Transmission confirmation.

The assignee of the present application submitted a spreadsheet of cases to the Electronic Business Center (EBC) to be associated with assignee's customer number. The EBC rejected the

Intarcia Dkt No. ALE 058.11
USSN: 09/627,531
PATENT

present application asserting that there was not an appropriate Power of Attorney. However, as can be seen from the accompanying papers, applicants have submitted a proper Power of Attorney for the present application, including evidence of chain of title.

The EBC informed the undersigned that it is the Examiner's responsibility to ensure that these papers were properly entered. Accordingly, please ensure that the electronic file record is updated as soon as possible.

Further, please associate the present application with **CUSTOMER NUMBER 000074866.**

Please direct all further communications in the application to:

CUSTOMER NUMBER 000074866

Barbara G. McClung, Esq.
Vice President, General Counsel and Corporate Secretary
Intarcia Therapeutics, Inc.
24650 Industrial Blvd
Hayward CA 94545
Phone: 510-782-7800 ext 296
Facsimile: 510-782-7801

If the Examiner notes any further matters that the Examiner believes may be expedited by a telephone interview, the Examiner is requested to contact the undersigned at (650) 780-9030.

Respectfully submitted,

Dated: 13 March 2008

By: Gary R. Fabian
Gary R. Fabian, Ph.D.
Registration No. 33,875
Agent for Applicants

**RECEIVED
CENTRAL FAX CENTER**Intarcia Dkt No. ALE 058.11
USSN: 09/627,531
PATENT**MAR 13 2008**

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)	
I hereby certify that this correspondence is being facsimile transmitted to the Commissioner for Patents, United States Patent and Trademark Office, (Fax No. 571-273-8300) on the date indicated.	
<i>Gary R. Fabian</i>	<u>28 January 2008</u>
Signature	Date of Transmittal

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE	
In Re Application of: BERRY, Stephen A., et al.	Confirmation No.: 3299
Serial No.: 09/627,531	Art Unit: 1618
Filing Date: 28 July 2000	Examiner: Fubara, B.M.
Title: Stable Non-Aqueous Single Phase Viscous Vehicles and Formulations Utilizing Such Vehicles	

**AUTHORIZATION TO CHARGE OR CREDIT DEPOSIT ACCOUNT AND
BLANKET PETITION FOR EXTENSION OF TIME**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

If a paper is untimely filed in this application or any continued prosecution application derived therefrom by applicant(s) or his/her/their representative, the Commissioner is hereby petitioned under 37 CFR § 1.136(a) for the minimum extension of time required to make said paper timely. In the event a petition for extension of time is made under the provisions of this paragraph, the Commissioner is hereby requested to charge any fee required under 37 CFR § 1.17(a)-(d) to Deposit Account No. **504212** (please reference docket number **ALE 058.11**). This, however, is not authorization to pay the Issue Fee.

Intarcia Dkt No. ALE 058.11
USSN: 09/627,531
PATENT

If a paper is concurrently or subsequently filed in this application or any continued prosecution application derived therefrom by applicant(s) or his/her/their representative and a fee under 37 CFR §§ 1.16-1.17 is required to effect any amendment, petition or other action requested in said paper, the Commissioner is hereby requested to charge any deficiency in said fee, or credit any overpayment of said fee, to Deposit Account No. 504212. This, however, is not authorization to pay the Issue Fee.

Respectfully submitted,



Dated: 28 January 2008

By :

Gary R. Fabian, Ph.D.
Registration No. 33,875
Agent for Applicants

Intarcia Therapeutics, Inc.
2000 Powell Street
Suite 1640
Emeryville, CA 94608
Phone: (510) 652-2600
Fax: (510) 652-2657